Roche falls in line in India

Swiss drugmaker to slash prices to avoid losing its exclusive rights

Swiss drugmaker Roche Holding plans to offer cutprice versions of two blockbuster cancer drugs for the Indian market soon, a company spokesman said on Friday, days after the government moved to slash the price of another cancer treatment.

India stripped German group Bayer of exclusive rights to Nexavar earlier this month and licenced a local company to produce a cheap, generic version, on the grounds that poor Indians could not otherwise afford the life-saving drug.

Roche, the world’s biggest maker of cancer drugs, said it would offer “significantly” cheaper, locally branded versions of its two cancer drugs, Herceptin and Mabthera, by early next year, under an alliance with India’s Emcure Pharmaceuticals.

“The scope is to enable access for a large majority of patients who currently pay out of pocket as well as to partner with the government to enable increased access to our products for people in need,” spokesman, Mr Daniel Grotzky, said by phone from the company’s headquarters in Basel, Switzerland.

Monthly doses of Herceptin, for breast cancer, and Mabthera, for cancers of the blood and lymph system, cost around $3,000 to $4,500 per patient at wholesale prices, Mr Grotzky said. “With this strategy, we expect to significantly increase the number of patients treated with our therapies and With this strategy, we expect to significantly increase the number of patients treated with our therapies or drugs and help those under treatment to continue to use our products properly — Daniel Grotzky, Spokesman,

Roche help patients currently under treatment to continue to use our products properly,” he added. The move highlights a growing debate about the cost of modern cancer medicines, which often work far better than traditional chemotherapy but come at a much high price.

In other areas of medicines — notably HIV/AIDS drugs for Africa — drug companies have already cut prices substantially. More recently, some firms, including GlaxosmithKline, have also been experimenting with discounts on certain products in middle-income countries. However, Roche has in the past argued that consumers everywhere should pay the same price for its cancer drugs. The firm said the cheaper versions would be renamed for the Indian market and be packed by Emcure Pharmaceuticals in an effort to gain market share, as reported in The Wall Street Journal earlier.

The decision to give the cheaper versions distinct names may help Roche limit the risk that wholesalers buy up the products and re-sell them. Under the deal, Roche will continue to make the drugs at its US, Singapore and Germany plants and ship them. — Reuters